ESMO Conference Coverage
Featured Articles
(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps...
Read Article
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
Read Article
Latest Articles
October 10, 2019
October 08, 2019
October 03, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
View More
News Commentary
Editor Image
01 Oct, 2019 | by H. Jack West, MD
The impact of the CheckMate-227 trial remains to be seen. While it was positive...
View Comment
Editor Image
01 Oct, 2019 | by H. Jack West, MD
An important result that should satisfy the holdouts who were waiting on a...
View Comment
View More
OBR Blog
There are no ESMO / ECC Conference Coverage blog entries.